New York, NY -- (SBWIRE) -- 11/29/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: American Capital Agency Corp (NASDAQ:AGNC), Novavax, Inc (NASDAQ:NVAX), Acasti Pharma Inc (NASDAQ:ACST), GDF Suez SA (ADR) (OTCMKTS:GDFZY)
American Capital Agency Corp (NASDAQ:AGNC) showed a volume of 9.32 million shares by the end of last trade whereas the average volume of the stock remained 7.65 million shares. The stock opened the session at $20.12 but then moved to $20.52. At that price, the stock showed a positive performance of 3.01%. American Capital Agency Corp. (AGNC) is a real estate investment trust (REIT). The Company earns income primarily from investing on a leveraged basis in agency mortgage-backed securities. These investments consist of residential mortgage pass-through securities and collateralized mortgage obligations (CMOs) for which the principal and interest payments are guaranteed by government-sponsored entities,
Will AGNC Continue To Move Higher? Find Out Here
Novavax, Inc (NASDAQ:NVAX) opened the session at $3.45 and closed the session at $3.56. The stock showed a positive performance of 3.49% in previous trading session. Traded with volume of 3.4 million shares in the prior session and the average volume of the stock remained 2.87 million shares. Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company’s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins.
For How Long NVAX will fight for Profitability? Read This Trend Analysis report
Acasti Pharma Inc (NASDAQ:ACST) opened the session at $1.28 and closed the session at $1.20. The stock showed a negative performance of -13.68% in previous trading session. Traded with volume of 1.95 million shares in the prior session and the average volume of the stock remained 32,031.00 shares. Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases.
Why Should Investors Buy ACST After the Recent Fall? Just Go Here and Find Out
GDF Suez SA (ADR) (OTCMKTS:GDFZY) the stock decreased -0.13% and finished the session at $23.34. Traded with volume of 68,676.00 shares in the prior session and the average volume of the stock remained 71,224.00 shares. The beta of the stock remained 1.20. GDF Suez SA is a France-based natural gas and electricity supplier. Its operations are organized in following business lines: Energy Europe, engaged in the production of electricity and distribution and supplying of gas through divisions in Benelux and Germany, the rest of European countries; Energy International which supplies North and Latin America,
Will GDFZY Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)